Changeflow GovPing Healthcare & Life Sciences Metabolic Selection via Serine Biosynthesis Pat...
Routine Notice Added Final

Metabolic Selection via Serine Biosynthesis Pathway Patent Application

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO has published a new patent application, US20260085327A1, related to metabolic selection via the serine biosynthesis pathway. The application details an isolated mammalian cell with reduced expression of Phosphoserine Phosphatase (PSPH) and its use in recombinant protein production.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application from the USPTO concerning a novel method for metabolic selection using the serine biosynthesis pathway. The application, titled 'Metabolic Selection via the Serine Biosynthesis Pathway,' describes an isolated mammalian cell engineered to have reduced or eliminated expression of Phosphoserine Phosphatase (PSPH). It also outlines methods for preparing these cells and utilizing them for the production of recombinant proteins.

As this is a patent application, it does not impose direct regulatory obligations on companies. However, it signifies potential future intellectual property developments in biotechnology and pharmaceutical manufacturing. Companies involved in recombinant protein production or cell-based therapies should be aware of this filing as it may impact future research, development, and commercialization strategies in this area.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METABOLIC SELECTION VIA THE SERINE BIOSYNTHESIS PATHWAY

Application US20260085327A1 Kind: A1 Mar 26, 2026

Inventors

Mary Otto, James Ravellette, David Razafsky, Jason A. Gustin, Trissa Borgschulte

Abstract

The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Phosphoserine Phosphatase (PSPH). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.

CPC Classifications

C12N 15/85 C07K 16/00 C12N 5/0682 C12N 9/226 C12N 9/93 C12N 15/111 C07K 2317/31 C12N 2310/20 C12N 2510/00 C12Y 301/03003 C12Y 603/01002 C12Y 603/05004

Filing Date

2023-09-29

Application No.

19112686

View original document →

Named provisions

Abstract

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 29th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085327A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Recombinant Protein Production Cell Engineering
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Biotechnology Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!